Know Cancer

or
forgot password

Diphenoxylate / Atropine to Decrease Bowel Activity During F-18 FDG PET


Phase 3
18 Years
N/A
Not Enrolling
Both
Lymphoma

Thank you

Trial Information

Diphenoxylate / Atropine to Decrease Bowel Activity During F-18 FDG PET

Inclusion Criteria


Inclusion Criteria

- Males and females 18 years of age or older

- Subjects pre-scheduled for clinically-indicated PET scan

- Subjects with newly diagnosed or recurrent untreated disease (lymphoma) based on
abdominal and/or pelvic adenopathy or masses on CT within 6 months of PET scan
Exclusion Criteria

- Allergy to Lomotil (Diphenoxylate hydrochloride, Atropine sulfate)

- Subjects with one or more episodes of diarrhea within 24 hours prior to PET scan

- Women who are breast-feeding

- Subjects with a history of severe liver disease, jaundice, dehydration, or
narrow-angle glaucoma

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic

Outcome Measure:

Reduction of bowel activity

Outcome Time Frame:

1hour

Safety Issue:

No

Authority:

United States: Mayo Clinic

Study ID:

2051-02

NCT ID:

NCT00583323

Start Date:

February 2003

Completion Date:

September 2005

Related Keywords:

  • Lymphoma
  • Lymphoma

Name

Location